From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again
Open Access
- 25 September 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 157 (3), 321-327
- https://doi.org/10.1093/ajcp/aqab135
Abstract
Monitoring is essential to safe anticoagulation prescribing and requires close collaboration among pathologists, clinicians, and pharmacists. We describe our experience in the evolving strategy for laboratory testing of unfractionated heparin (UFH). An intrainstitutional investigation revealed significant discordance between activated partial thromboplastin time (aPTT) and antifactor Xa (anti-Xa) assays, prompting a transition from the former to the latter in 2013. With the increasing use of oral factor Xa inhibitors (eg, apixaban, rivaroxaban, edoxaban, betrixaban), which interfere with the anti-Xa assay, we adapted our protocol again to incorporate aPTT in patients admitted on oral Xa inhibitors who require transition to UFH. Our experience demonstrates key challenges in anticoagulation and highlights the importance of clinical pathologists in helping health systems adapt to the changing anticoagulation landscape.Keywords
Funding Information
- National Center for Advancing Translational Sciences (KL2TR003097)
This publication has 41 references indexed in Scilit:
- Activated Partial Thromboplastin Time and Anti-Xa Measurements in Heparin MonitoringAmerican Journal of Clinical Pathology, 2013
- A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor XaNature Medicine, 2013
- Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literatureThrombosis Research, 2012
- Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated HeparinPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin timeJournal of Thrombosis and Haemostasis, 2009
- Laboratory Monitoring of Heparin Therapy: Partial Thromboplastin Time or Anti-Xa Assay?Laboratory Medicine, 2009
- Monitoring unfractionated heparin with the aPTT: Time for a fresh lookThrombosis and Haemostasis, 2006
- To bleed or not to bleed? is that the question for the PTT?Journal of Thrombosis and Haemostasis, 2005
- A Prospective Study of the Value of Monitoring Heparin Treatment with the Activated Partial Thromboplastin TimeThe New England Journal of Medicine, 1972